Algeta for investors
Algeta aims to be an attractive investment for its shareholders through consistent performance and information.
Algeta is an oncology company seeking to bring novel targeted medicines to patients through its leadership in alpha-pharmaceuticals.
Algeta was founded in 1997 and listed on the Oslo Stock Exchange in 2007 (ticker: ALGETA). Since then Algeta has developed expert capabilities in its operational areas of research and development, manufacturing, clinical, and commercial. With global clinical operations, it has also established a subsidiary in the US to carry out the co-promotion of its lead product radium-223 dichloride, as part of its 2009 agreement with Bayer.
"Our goal is to develop cancer therapies where there are clear, unmet medical needs"
Our research
Combining expertise in radiochemistry, nuclear medicine, and medical oncology, Algeta is at the forefront of alpha-pharmaceutical research.
Contact us
If you'd like to know more about Algeta and our research, please do get in touch – we'd love to hear from you.